Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
ICD-10 I67.850 is a billable code used to indicate a diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary condition characterized by progressive degeneration of small blood vessels in the brain, leading to recurrent strokes, cognitive decline, and psychiatric symptoms. The condition is caused by mutations in the NOTCH3 gene, which affects vascular smooth muscle cells. Clinically, patients may present with migraines, mood disturbances, and progressive dementia, often beginning in mid-adulthood. The disease progression typically involves the development of subcortical infarcts and leukoencephalopathy, observable through neuroimaging techniques such as MRI, which reveal white matter changes and lacunar infarcts. Diagnostic considerations include family history, clinical symptoms, and genetic testing for NOTCH3 mutations. Early diagnosis is crucial for management and counseling of affected individuals and their families, as the condition is inherited in an autosomal dominant pattern.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
I67.850 specifically covers CADASIL, which includes symptoms such as recurrent strokes, cognitive impairment, and psychiatric disorders due to small vessel disease in the brain.
I67.850 should be used when CADASIL is confirmed through genetic testing or when clinical features strongly suggest this condition, differentiating it from other cerebrovascular diseases.
Documentation should include a detailed family history of cerebrovascular disease, clinical symptoms consistent with CADASIL, neuroimaging findings, and results from genetic testing for NOTCH3 mutations.
